Clinical Trial

Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This phase III trial studies how well response and biology-based risk factor-guided therapy works in treating younger patients with non-high risk neuroblastoma. Sometimes a tumor may not need treatment until it progresses. In this case, observation may be sufficient. Measuring biomarkers in tumor cells may help plan when effective treatment is necessary and what the best treatment is. Response and biology-based risk factor-guided therapy may be effective in treating patients with non-high risk neuroblastoma and may help to avoid some of the risks and side effects related to standard treatment.
Protocol Amendment History 53 amendments
This ClinicalTrials.gov record has been amended 53 times since 2014-06-26; most recent amendment 2026-05-01.
Status change: Recruiting → Active, Not Recruiting 2023-08-01
Status change: Not Yet Recruiting → Recruiting 2014-08-07
Trial Details
NCT Number NCT02176967
Lead Sponsor Children's Oncology Group
Collaborators: National Cancer Institute (NCI)
Conditions Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Neuroblastoma
Enrollment 621 participants
Start Date 2014-08-08
Primary Completion 2026-09-30 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-05